Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement ...
Cartesian Therapeutics has claimed a phase 2b win for its BCMA-directed CAR-T therapy in generalized myasthenia gravis (gMG). But the biotech’s victory came on a primary endpoint it changed in May and ...
The use of Cartesian and six-axis robots, as well as selective-compliance-articulated robot arms (SCARAs) is on the rise. They automate tasks to accelerate cycle times, increase throughput, and ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Cartesian Therapeutics, Inc. (RNAC) 25th Annual Needham Virtual Healthcare Conference April 13, 2026 9:30 AM EDTCompany ParticipantsCarsten Brunn ...
Cartesian Therapeutics updates on Descartes-08 trials in myasthenia gravis and lupus, with financial results highlighting $182.1 million in cash. Cartesian Therapeutics, Inc. has announced the ...
Supposing you were in the market for a prototype of a circuit board here in 2013 – what kind of process would you have to go through to get one? Certainly one that'd require one whole heck of a lot ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results